Medicare announces price cuts for 15 prescription drugs, including Ozempic

CMS announced negotiated Medicare prices for 15 high-cost outpatient drugs under the Inflation Reduction Act, cutting prices (30-day supply) for products such as Ozempic/Wegovy from $959 to $274 and many oncology and respiratory drugs by roughly 40–60%; the changes take effect in 2027. CMS estimates $12 billion in taxpayer savings and $685 million in reduced out-of-pocket costs for enrollees in 2027; the impacted drugs represented $42.5 billion (15%) of Part D spending in 2024. Drugmakers can opt out but risk losing Medicare market access and have mounted legal challenges to the program; the negotiation contrasts with the Trump administration’s separate voluntary tariff-relief deal with Novo Nordisk.

Analysis

Market structure: The CMS cuts are a direct negative for branded manufacturers with high Medicare Part D exposure (Novo Nordisk/NVO is the leading visible candidate) and a tailwind for payers/PBMs (UNH, CVS, CI) that will see lower drug spend. The negotiated Ozempic/Wegovy price (~$274 vs $959 list, ~71% cut) is a concentrated hit but applies to 15 drugs that were $42.5bn (15% of Part D) in 2024 — meaningful for US revenue but not an immediate global revenue wipeout. Competitive dynamics shift pricing power toward payers; manufacturers face margin compression but may offset some loss via increased volume, formulary placement, or accelerated international launches.

Risk assessment: Tail risks include manufacturers withdrawing drugs from Medicare (sales lost), expansion of the negotiation list to larger revenue pools, or adverse court rulings that change implementation timing; each could move equity and credit spreads 100–300 bps. Timing: expect immediate headline volatility (days), earnings/guidance revisions in the next 1–3 quarters, and persistent margin pressure over 2–5 years. Hidden dependencies include Medicare’s actual share of each drug’s sales, existing rebate contracts, and spillover into commercial pricing — monitor company-level Medicare revenue share (thresholds: >20% material).

Trade implications: Direct short/hedge candidates—NVO (high direct exposure); long insurers/PBMs—UNH/CVS. Options: buy 9–12 month NVO put protection or put spreads to cap cost (buy 10% OTM puts, sell 25% OTM puts) sized to cover 30–50% of exposure. Pair trade: short NVO vs long UNH (1:1 or risk-weighted) over a 3–9 month horizon to capture payer margin tailwind versus manufacturer squeeze.

Contrarian angles: The market may overprice permanent global revenue loss — Medicare Part D patients are older and may represent <20% of GLP‑1 volume today; a >12–15% NVO equity selloff could be an attractive re-entry if company-specific Medicare share data comes in low. Historical parallels (headlines driving temporary sell-offs, e.g., insulin pricing debates) suggest 6–12 month mean reversion is possible if litigation stalls or manufacturers retain market access. Unintended consequence: accelerated M&A and geographic price segmentation could restore earnings power over 12–36 months.

Key Decisions for Investors

• Reduce existing NVO long exposure by ~40% within 72 hours and hedge the remainder by purchasing 9–12 month put protection sized to cover 40% of pre-hedge exposure (buy 10% OTM puts; consider pairing with selling 25% OTM puts to fund premium). Close hedge if NVO falls ≥12% or implied volatility compresses ≥30% from current levels.
• Establish a 2.5% portfolio long in payers/PBMs: UNH 1.25% and CVS 1.25% on a 6–12 month horizon to capture margin tailwind from lower Part D payments; set sell targets to trim at +12–15% absolute appreciation or if guidance worsens.
• Implement a pair trade: short NVO equal notional 1.0% vs long UNH 1.0% (risk-weight to equity beta) for a 3–9 month horizon; unwind if NVO outperforms UNH by >12% or if CMS publishes manufacturer-specific Medicare share showing NVO exposure <15% within 60 days.
• Opportunistic buy-on-dip rule: if NVO drops >15% within 30 trading days and CMS/companies report Medicare share for Ozempic/Wegovy <20% within 60 days, initiate a 2.0% tactical long (stock or 6–12 month calls) anticipating mean reversion over 6–12 months.